Is Erectile Dysfunction a Reliable Proxy of General Male Health Status? The Case for the International Index of Erectile Function—Erectile Function Domain

Objective: The aim of this study is to investigate the effect of hyperlipidemia on the development of erectile dysfunction (ED) in hyperlipidemic patients with ED. Materials and Methods: Twenty-five patients who applied to the radiology clinic were included in the study. All patients have only hyperlipidemia as a risk factor of ED. The patients were evaluated in terms of ED by using International Index of Erectile Function (IIEF) form. Before and after oral treatment with daily doses of 10 mg atorvastatin, all parameters were measured. Paired t-test was used to compare vascular velocities between lipid profiles and Erectile Function Domain Scores (EFDS) and IIEFs, before and after treatment separately. Results: Cholesterol levels of 96% of patients were higher than 200 mg/dl and 52% of them had abnormal penile Doppler ultrasonography (PDU) findings. Patients with abnormal PDU findings had lower cholesterol levels than those with normal PDU findings. Significant differences existed between patients with normal and abnormal PDU in the high triglyceride group as for pre-, and post-treatment values . Pre-, and post-treatment EFD and IIEF scores were comparable. Conclusion: It can be said that a relationship exists between hyperlipidemia and erectile dysfunction. Therefore, lipid profile of a patient admitted with ED may be analyzed routinely

Download Full-text

Abstract 18240: Poor Sexual Outcome Among Male ICD Patients Who Have Received Shock and Antitachycardia Pacing Therapy

Circulation ◽

10.1161/circ.132.suppl_3.18240 ◽

2015 ◽

Vol 132 (suppl_3) ◽

Author(s):

Pernille Palm Johansen ◽

Ann-Dorthe Zwisler ◽

Jesper Hastrup Svendsen ◽

Selina K Berg

Keyword(s):

Erectile Dysfunction ◽

Primary Prevention ◽

Secondary Prevention ◽

Erectile Function ◽

Test Reliability ◽

Antitachycardia Pacing ◽

Cross Sectional ◽

Scale Range ◽

Male Patients ◽

Function Domain

Purpose: To investigate (i) the prevalence of erectile dysfunction (ED) in male patients with implantable cardioverter defibrillator (ICD), and (ii) the association between ICD, indication, therapy and poor sexual outcome. Methods: This cross-sectional study included male patients with ICD. Inclusion criteria were NYHA I-II. Exclusion criteria were no partner and no known urinary tract diseases. Participants completed the International Index of Erectile Function questionnaire that concerns sexual function and meet psychometric criteria for test reliability and validity. The study was conducted as a postal survey and questionnaires were mailed out to 818 patients from two university hospitals. Data on indication (primary prevention vs secondary prevention) and therapy (shock and antitachycardia pacing ) was collected from local databases. Results: Data from the 370 responders (response rate 45.2 %) were analyzed. Mean age of patients was 63.9 ± 12.1. International Index of Erectile Function total mean score was 39.6 ± 24.2 (scale range 5 to 75, with higher score indicating better function). The Erectile Function domain mean score was 14.5 ± SD 11.5 (Scale range 1 to 30). The Erectile Function domain was distributed between 48.9 % having severe ED, 7.6 % moderate ED, 7.0 % moderate to mild ED, 7.0 % mild ED and 29.5 % having no ED. Age was highly associated with ED (OR 0.91, 95% CI: 0.88-0.93). Adjusted for age, ED was associated with therapy from the ICD (OR 1.84, 95% CI: 1.07-3.2) and primary prevention indication (OR 1.90, 95% CI: 1.19 - 3.06) compared to patients having an ICD on secondary prevention indication. Conclusions: Erectile dysfunction was present in more than 70 % of male patients with ICD and more than 48 % had severe erectile dysfunction, resulting in inability to perform a sexual intercourse. Age, primary prevention indication and therapy from the ICD were all associated with a poor sexual outcome.

Download Full-text

Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials

American Journal of Men s Health ◽

10.1177/1557988319880764 ◽

2019 ◽

Vol 13 (5) ◽

pp. 155798831988076

Author(s):

Jinze Li ◽

Lei Peng ◽

Dehong Cao ◽

Lujia He ◽

Yunxiang Li ◽

...

Keyword(s):

Erectile Dysfunction ◽

Erectile Function ◽

Meta Analysis ◽

Cochrane Library ◽

Controlled Trials ◽

Present Evidence ◽

Randomized Controlled ◽

Drug Of Choice ◽

Function Domain ◽

Larger Sample

Previous studies have reported the clinical efficacy of avanafil for erectile dysfunction (ED), but these findings are controversial. This study aims to investigate the safety and efficacy of avanafil for ED. EMBASE, PubMed, and Cochrane Library were searched extensively to obtain eligible studies. Clinical outcomes including successful vaginal penetration (SVP), successful intercourse (SI), International Index of Erectile Function-Erectile Function domain (IIEF-EF) score and treatment adverse events (TAEs) were compared using RevMan v.5.3. Eight RCTs involving 3,709 patients were included. The analysis demonstrated that compared with placebo, the SVP (RR = 3.20, 95% CI [2.60, 3.95], p < .001), SI (RR = 2.53, 95% CI [2.19, 2.92], p < .001), change in IIEF-EF score (MD = 4.57, 95% CI [3.68, 5.46], p < .001) and TAEs (RR = 1.78, 95% CI [1.38, 2.31], p < .0001) were significantly higher in the avanafil. In addition, avanafil 200 mg were higher than avanafil 100 mg in SI (RR = 0.86, 95% CI [0.75, 0.99], p = .03) and change in IIEF-EF score (MD = −1.34, 95% CI [−1.67, −1.01], p < .001), but there were no obvious differences in SVP (RR = 0.89; 95% CI [0.74, 1.08], p = .23) and TAEs (RR = 0.97, 95% CI [0.83, 1.14], p = .74) between the two doses. The present evidence suggests that avanafil (especially 200 mg) has the potential to be the drug of choice for ED, but more strict and larger sample size RCTs are need to validate the findings.

Download Full-text

Tadalafil Improves Erectile Dysfunction and Quality Of Life in Men with Cirrhosis: A Randomized Placebo Controlled Trial

10.21203/rs.3.rs-695249/v1 ◽

2021 ◽

Author(s):

Rakesh K Jagdish ◽

Ahmed Kamaal ◽

Saggere M Shasthry ◽

Jaya Benjamin ◽

Rakhi Maiwall ◽

...

Keyword(s):

Quality Of Life ◽

Erectile Dysfunction ◽

Erectile Function ◽

Controlled Trial ◽

Sf 36 ◽

High Prevalence ◽

Function Domain ◽

Anxiety Depression ◽

Satisfaction Domain

Abstract Background and Aims: Patients with cirrhosis have high prevalence of erectile dysfunction (ED). The aim of this study was to study the efficacy and safety of tadalafil for ED in patients with cirrhosis. Methods: 140 cirrhotic males with ED were randomized into tadalafil 10 mg daily (n = 70) or placebo (n = 70) for 12 weeks. ED was diagnosed if erectile function (EF) domain score was < 25 in International Index of Erectile Function (IIEF) questionnaire. Primary outcome was proportion of patients having an increase in > 5 points in EF domain of the IIEF. Results: At end of 12 weeks, more patients in tadalafil group achieved > 5 points increase in the EF domain of the IIEF as compared to the placebo group [44(62.9%) vs. 21(30%), P < 0.001]. At the end of 12 weeks, patients receiving tadalafil had significantly more change in scores on the erectile function domain, orgasmic function domain, intercourse satisfaction domain, overall satisfaction domain, erection vaginal penetration rates and successful intercourse; significantly more decline in the GAD-7 and PHQ- 9 scores; significantly more improvement in scores of five of the eight domains of SF-36 (general health perception, vitality score, social functioning, role emotional, and mental health), and the mental component summary rates as compared to placebo. The development of side effects and the changes in HVPG were not significantly different between the two groups. Conclusions: Tadalafil therapy significantly enhanced erectile function, improved anxiety, depression and quality of life, and was well tolerated by cirrhotic men with ED. (ClinicalTrials.gov identifier number: NCT03566914; first posted date: June 25, 2018).

Download Full-text

Impact of Testosterone Therapy on hypogonadal patients unresponsive to phosphodiesterase-5 inhibitors alone: A systematic review and a meta-analysis

10.21203/rs.3.rs-962013/v1 ◽

2021 ◽

Author(s):

Xiaowei Yu ◽

Yanhong Liu ◽

Xiaoyuan Zhang ◽

Qun Wang

Keyword(s):

Erectile Dysfunction ◽

Treatment Group ◽

Erectile Function ◽

Domain Score ◽

Cochrane Library ◽

Testosterone Therapy ◽

Phosphodiesterase 5 Inhibitors ◽

Function Domain ◽

Phosphodiesterase 5 ◽

Dual Treatment

Abstract Background Phosphodiesterase-5 inhibitors as the first-line treatment for erectile dysfunction, when patients with hypogonadism fail to respond to phosphodiesterase-5 inhibitors, the beneficial of addition testosterone therapy is a major concern for clinicians. The objective of this study was to collect and summarize the evidence that evaluated the benefit of addition testosterone therapy in hypogonadism fail to respond to phosphodiesterase-5 inhibitors. Methods Electronic literature searches of Cochrane Library, PubMed, MEDLINE and EMBASE databases were conducted up to October 2020 and included randomized controlled trials. Specifically, we were looking for papers where Erectile Function Domain Score differences between pre and post-treatment were used as the primary outcome after treatment of testosterone therapy alone, phosphodiesterase-5 inhibitors therapy alone, or a dual treatment of both testosterone therapy and phosphodiesterase-5 inhibitors. Secondary outcomes included the number of phosphodiesterase-5 inhibitors non-responders who subsequently reported a satisfactory treatment of dual treatment with testosterone therapy and phosphodiesterase-5 inhibitors. Results A total of 4 studies that met our criteria, consisting of 326 patients. The Erectile Function Domain Score was significantly higher after treatment of testosterone combine with phosphodiesterase-5 inhibitors(4.88[4.18–5.57]), phosphodiesterase-5 inhibitors with placebo(3.15[1.82–4.47]), and testosterone monotherapy (2.04[0.38–3.71]) compared with baseline. Dual treatment with testosterone and phosphodiesterase-5 inhibitors significantly improved Erectile Function Domain Score when compared with testosterone monotherapy (3.16, 95% CI: 1.79–4.53), Of 41.7% patients in the dual treatment group reported an improvement, compared to only 33.0% in phosphodiesterase-5 inhibitors treatment group. Conclusions Combination therapy of testosterone and phosphodiesterase-5 inhibitors seems most effective in men with both erectile dysfunction and hypogonadism who initial unrespond to phosphodiesterase-5 inhibitors.

Download Full-text